By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
latest_posts
- 1
There’s ‘super flu,’ COVID, RSV. Is it going around in SoCal? - 2PFAS in pregnant women’s drinking water puts their babies at higher risk, study finds
- 3The Best Computer games Ever
- 410 Setting up camp Shelters That Offer Both Excellence and Isolation
- 5The Minimized Passage Horse: Reconsidering a Symbol for the Cutting edge Period
- Avoid Large Crowds In Bali & Swim At This Peaceful Waterfall With A Gorgeous, Natural Pool
- Remain Fit: Powerful Wellness and Work-out Schedules for a Better You
- Russia Fields New Ulan-2 All-Terrain Tactical Vehicle
- U.K. blocks Kanye West from entering Britain to headline now canceled festival: What led to the ban
- ‘Integral part of our nation’: Herzog visits Franciscan Sisters in Jerusalem ahead of Christmas
- ISS astronaut evacuation shouldn't interfere with upcoming Artemis 2 moon mission, NASA chief says
- How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- Language Learning Stages: Which One Gets Your Vote?
- Scientists Just Discovered Japan’s First New Bird Species in Over 40 Years
